Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms …

B Williams, TM MacDonald, SV Morant… - The lancet Diabetes & …, 2018 - thelancet.com
Background In the PATHWAY-2 study of resistant hypertension, spironolactone reduced
blood pressure substantially more than conventional antihypertensive drugs. We did three …

[HTML][HTML] Antihypertensive medications are associated with the risk of kidney and bladder cancer: a systematic review and meta-analysis

Y Xie, P Xu, M Wang, Y Zheng, T Tian, S Yang… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
Several studies have indicated that the use of antihypertensive medications may influence
the incidence of bladder/kidney cancer, with some scholars refuting any such association …

Antihypertensive drugs and cancer risk

S Kidoguchi, N Sugano, T Yokoo… - American Journal of …, 2022 - academic.oup.com
Hypertension is the most prevalent comorbidity in cancer patients. Consequently, many
cancer patients are prescribed antihypertensive drugs before cancer diagnosis or during …

Association of spironolactone use with risk of cancer: a systematic review and meta-analysis

K Bommareddy, H Hamade, MA Lopez-Olivo… - JAMA …, 2022 - jamanetwork.com
Importance While originally approved for the management of heart failure, hypertension, and
edema, spironolactone is commonly used off label in the management of acne, hidradenitis …

Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response

A Gold, L Eini, M Nissim-Rafinia, R Viner, S Ezer… - Oncogene, 2019 - nature.com
The cancer stem cell (CSC) model suggests that a subpopulation of cells within the tumor,
the CSCs, is responsible for cancer relapse and metastasis formation. CSCs hold unique …

[HTML][HTML] Protective role of mineralocorticoid receptor signaling in urothelial tumorigenesis

Y Nagata, T Matsukawa, T Goto… - American Journal of …, 2023 - ncbi.nlm.nih.gov
The expression status of mineralocorticoid receptor (MR) and its biological significance in
human urothelial carcinoma remain unknown. The present study aimed to determine the …

[HTML][HTML] Mineralocorticoid receptor signaling inhibits bladder cancer progression

Y Nagata, T Goto, Y Teramoto… - American Journal of …, 2024 - ncbi.nlm.nih.gov
The biological or clinical significance of mineralocorticoid receptor (MR) in urothelial cancer
remains largely unknown. The present study aimed to determine the functional role of MR in …

Spironolactone use is associated with lower prostate cancer risk: a population-wide case-control study

K Beckmann, H Garmo, B Lindahl… - Prostate cancer and …, 2020 - nature.com
Background Spironolactone, a cheap effective diuretic used to manage hypertension and
heart failure, also has anti-androgenic effects through its non-selective binding to steroid …

The risk for prostate cancer with calcium channel blockers: a systematic review, meta-analysis, and meta-regression

V Rotshild, N Rabkin, I Matok - Annals of Pharmacotherapy, 2023 - journals.sagepub.com
Background For decades, conflicting results were published regarding the increased risk of
Prostate cancer (PCa) among calcium channel blocker (CCB) users. Objective We aimed to …

[HTML][HTML] The association between Type 1 diabetes mellitus and periodontal diseases

KT Sun, SC Chen, CL Lin, JT Hsu, IA Chen… - Journal of the Formosan …, 2019 - Elsevier
Background/purpose Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease
affecting oral health. Evidence shows possible association between T1DM and periodontal …